Hikma Pharmaceuticals plc (LON:HIK) (NASDAQ Dubai:HIK) (OTC:HKMPY) announced on Thursday the approval of KLOXXADO (naloxone HCl) Nasal Spray 8 mg by Health Canada for treating opioid overdoses in adult patients.
The nasal spray delivers 8 mg of naloxone hydrochloride per dose to reverse opioid overdose effects, such as respiratory and central nervous system depression.
Under a six-year commercial agreement, Emergent BioSolutions Inc (NASDAQ:EBS) will lead the marketing and sales of KLOXXADO in Canada, where it aims to increase access to intranasal naloxone. Emergent will work with Canadian agencies and private payers to make KLOXXADO available by prescription as early as 2026.
Hikma will continue to manufacture KLOXXADO at its Columbus, Ohio facility and supply it exclusively to Emergent for commercialisation. The approval of KLOXXADO Nasal Spray comes at a time when Health Canada has reported a decrease in overdose deaths, partly attributed to expanded naloxone distribution.
Amgen's IMDELLTRA shows superior overall survival in small cell lung cancer trial
VARON expands access to home oxygen concentrators
SciTech Development secures second FDA clearance for ST-001 in early-stage cancer trials
Mabwell's B7-H3-targeting ADC clinical trial application receives Chinese regulatory approval
Dupixent receives approval in Japan as first biologic for COPD treatment
Vast Therapeutics' ALX1 drug candidate granted QIDP designation by US FDA
Actinium Pharmaceuticals signs Ac-225 radioisotope agreement with Eckert & Ziegler
GSK's Nucala (Mepolizumab) COPD application accepted by EMA
Everest Medicines' EVM14 IND application receives US FDA approval
Clover Biopharmaceuticals' SCB-1019 IND application receives US FDA approval
CStone Pharmaceuticals submits Type II variation application to EMA for sugemalimab
Hikma announces Health Canada approval of KLOXXADO Nasal Spray for opioid overdose treatment
Johnson & Johnson reports breakthrough overall survival data for EGFR-mutated lung cancer treatment